Biovitrum AB: research and development of small molecule drugs; process development and manufacture of recombinant protein drugs for metabolic diseases (obesity, type 2 diabetes)

Visit the company website www.biovitrum.com for full information.

Biovitrum is one of Europe's largest biotechnology companies. Of our 575 employees, more than 450 are scientists. The company is active in the research and development of small molecule drugs andÝin process development and manufacture of recombinant protein drugs. Drug research is concentrated on metabolic diseases, such as obesity and type 2 diabetes.

Formerly part of Pharmacia, Biovitrum combines the capabilities of a large company with the speed and innovation of an entrepreneurial startup. We benefit from broad experience and an extensive network of external partners. In collaboration with smaller players, we develop new candidate drugs up to the proof of concept stage. Then, in collaboration with large pharmaceutical companies, we continue our projects, finally bringing new drugs to the market.

The members of our Biopharmaceuticals team pioneered the field of process development and protein manufacture. Through its expert knowledge and wide-ranging capabilities, Biovitrum offers highly qualified process development and production of new protein-based drugs, on a contractual basis.

www.biovitrum.com